

SpecialtyRx.GiantEagle.com 1-844-259-1891

<u>Patient</u>	In	torm	ati	ion

New Patient Current Patient				
Patient's Name				
First Last MI				
Male Female				
Last 4 digits of SSN Date of Birth				
Street Address				
City State ZIP				
Preferred Phone Landline Mobile				
Alternate Phone Landline Mobile				
Preferred Method of Contact Call Text				
Email Address				
Patient's Primary Language English Other If other, please specify				
Parent/Guardian Name (if under 18)				
Home Phone Cell Phone				
Email Address				
Alternate Caregiver/Contact				
OK to speak to/leave message with alternate caregiver/contact				
Home Phone Cell Phone				
Email Address				
PLEASE ATTACH COPY OF FRONT AND BACK OF PATIENT'S INSURANCE CARD				
<u>Prescriber Information</u>				
Date Prescription Needed				
Ship to Office Patient Pickup at Retail Ship to Home				
Office Hours to Receive Shipment of Medication				
Office Contact and Title				
Office Contact Phone				



Patient's Name

First	Last		MI	
Date of Birth				
Primary ICD-10 code	Has the patient be	een on this therapy	before? Yes No	
If yes, please indicate start date	Height:	cm Weight:	kg Date Recorded:	
TB Test Results and Date:				
Has Hepatitis B been ruled out? Yes	No Date:			
If No, has treatment been initiated? Yes	s No			
New therapy induction Therapy c	hange			
Other therapies tried and failed:				
Corticosteroids Date:				
Methotrexate Date:				
Hydroxychloroquine Date:				
Leflunomide Date:		_		
Azathioprine Date:				
Sulfasalazine Date:				
Other biologics			Date:	
Other			Date	
Additional justification for drug				
NKDA Known drug allergies				
Concurrent Medications				

Prescribing Information

Medication	Strength	Directions	Qty/Refills
Actemra (tocilizumab) ADULT Patient weightkg	☐ 162mg/0.9mL prefilled syringe☐ 162mg/0.9mL ACTpen	☐ Inject 162mg subcutaneously every other week ☐ Inject 162mg subcutaneously every week	Qty: 2 devices 4 devices 6 devices 12 devices Refills:
Actemra (tocilizumab) PEDIATRIC Patient weightkg	162mg/0.9mL prefilled syringe162mg/0.9mL ACTpen	☐ Inject 162mg subcutaneously every three weeks ☐ Inject 162mg subcutaneously every two weeks	Qty: devices Refills:



Prescribing Information Cont.

Medication	Strength	Directions	Qty/Refills
Cimzia (certolizumab pegol)	Starter: 200mg/mL prefilled syringes (1 kit = 6 syringes, 3 doses)	Starter: Inject 400mg subcutaneously at weeks 0, 2, and 4	Qty: 1 kit Refills: 0
	Maintenance: ☐ 200mg/mL prefilled syringes (total dose = 400mg)	Maintenance: Inject the contents of 2 syringes (400mg) subcutaneously every 4 weeks Inject the contents of 1 syringe (200mg) subcutaneously every 2 weeks	Qty: 2 syringes 6 syringes Refills:
Cosentyx (secukinumab) ADULT	☐ 150mg/mL prefilled syringe ☐ 150mg/mL Sensoready auto-injector	Starter: Inject 150mg subcutaneously once weekly at week 0, 1, 2, 3, and 4, then 150mg every 4 weeks Inject 300mg subcutaneously once weekly at week 0, 1, 2, 3, and 4, then 300mg every 4 weeks	Qty: 5 devices 10 devices Refills: 0
		Maintenance: Inject 150mg subcutaneously once every 4 weeks Inject 300mg subcutaneously once every 4 weeks	Qty: 1 device 2 devices 3 devices 6 devices Refills:
Cosentyx (secukinumab) PEDIATRIC Patient weightkg	Shoc every 4 weeks	Qty: 5 devices Refills: 0	
		☐ Inject 75mg subcutaneously once every 4 weeks ☐ Inject 150mg subcutaneously once every	Qty: 1 device 3 devices Refills:
Enbrel (etanercept)	□ 25mg/0.5mL vial □ 25mg/0.5mL prefilled syringe □ 50mg/mL prefilled syringe □ 50mg/mL Sureclick auto-injector □ 50mg/mL Mini Cartridge	☐ Inject 50mg subcutaneously once weekly ☐ Other:	Qty: 4 devices 12 devices Other: Refills:



Prescribing Information Cont.

Medication	Strength	Directions	Qty/Refills
Humira (adalimumab) ADULT	Starter: CITRATE FREE Psoriasis/Uveitis or adolescent HS Starter Kit (1x 80mg/0.8mL and 2x 40mg/0.4mL) pen-injector HS Starter Kit (3x 80mg/0.8mL) pen-injector	Psoriasis/Uveitis/adolescent HS Starter: Inject 80mg as a single dose, then inject 40mg subcutaneously every other week beginning 1 week after the initial dose HS Starter: Inject 160mg subcutaneously followed by 80mg subcutaneously 2 weeks later on Day 15	Qty: 1 starter kit Refills: 0
	Maintenance: CITRATE FREE 40mg/0.4mL pen-injector 80mg/0.8mL pen-injector ORIGINAL FORMULATION 40mg/0.8mL pen-injector 40mg/0.8mL pen-injector	Maintenance: Inject 40mg subcutaneously every other week Inject 40mg subcutaneously every week Inject 80mg subcutaneously every other week	Qty: 2 devices 6 devices Other (must be in multiples of 2) Refills:
Humira (adalimumab) PEDIATRIC Patient weightkg	CITRATE FREE 10mg/0.1mL prefilled syringe 20mg/0.2mL prefilled syringe 40mg/0.4mL pen-injector 40mg/0.4mL prefilled syringe	☐ Inject 10mg subcutaneously every other week ☐ Inject 20mg subcutaneously every other week ☐ Inject 40mg subcutaneously every other week	Qty: 2 devices 6 devices Other (must be in multiples of 2) Refills:
	200mg/1.14mL prefilled pen 200mg/1.14mL prefilled syringe 150mg/1.14mL prefilled pen 150mg/1.14mL prefilled syringe	☐ Inject 200mg subcutaneously once every 2 weeks ☐ Inject 150mg subcutaneously once every 2 weeks	Qty: 2 devices 6 devices Refills:
Other:			Qty:



Prescriber Name			
Phone		Fax	
Email Address			
Office Address			
City	State	ZIP	
State License	DEA	NPI	
In order for brand name to be Necessary" in the space belo	e dispensed, prescriber must ho w:	and write "Brand Medically N	ecessary" or "Brand
· · · · · · · · · · · · · · · · · · ·	nd for Giant Eagle Specialty Pho ance prior authorization proces		es to act as an agent to
Prescriber signature required.	NO STAMPS. Prescriber attests	this is his/her legal signature	
Prescriber signature		Date	